Employees: 03 (2023.0)Legal category: 6599Size: PMECreation date: 2010-10-13 (15 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: MANOSQUE (04100), Alpes-de-Haute-Provence
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE BN-SEPT N : revenue, balance sheet and financial ratios
PHARMACIE BN-SEPT N is a French company
founded 15 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MANOSQUE (04100),
this company of category PME
shows in 2025 a net income positive of 19 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE BN-SEPT N (SIREN 527601926)
Indicator
2025
2024
2023
2022
2021
2020
2019
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
18 687 €
168 391 €
170 786 €
238 051 €
248 877 €
33 160 €
-191 925 €
49 716 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE BN-SEPT N generates positive net income of 19 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 50 k€ -> 19 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
18 687 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 36%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 62%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
35.934%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
62.069%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2019
2020
2021
2022
2023
2024
2025
Debt ratio
234.103
161.82
117.473
74.882
45.338
48.274
41.66
35.934
Financial autonomy
26.985
32.917
38.025
51.576
59.312
56.156
60.927
62.069
Repayment capacity
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
35.932025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good
In 2025, the debt ratio of PHARMACIE BN-SEPT N (35.93) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
62.07%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good
In 2025, the financial autonomy of PHARMACIE BN-SEPT N (62.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 98.95. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
98.955
Liquidity indicators evolution PHARMACIE BN-SEPT N
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
202.435
140.977
94.801
184.561
174.631
110.094
112.644
98.955
Interest coverage
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
98.952025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Watch
In 2025, the liquidity ratio of PHARMACIE BN-SEPT N (98.95) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Positioning of PHARMACIE BN-SEPT N in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE BN-SEPT N is estimated at
296 845 €
(range 201 440€ - 465 791€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
201k€296k€465k€
296 845 €Range: 201 440€ - 465 791€
NAF 5 année 2025
Valuation method used
Net Income Multiple
18 687 €
×
15.9x
=296 845 €
Range: 201 441€ - 465 791€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE BN-SEPT N with other companies in the same sector:
Frequently asked questions about PHARMACIE BN-SEPT N
What is the revenue of PHARMACIE BN-SEPT N ?
The revenue of PHARMACIE BN-SEPT N is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMACIE BN-SEPT N profitable?
Yes, PHARMACIE BN-SEPT N generated a net profit of 19 k€ in 2025.
Where is the headquarters of PHARMACIE BN-SEPT N ?
The headquarters of PHARMACIE BN-SEPT N is located in MANOSQUE (04100), in the department Alpes-de-Haute-Provence.
Where to find the tax return of PHARMACIE BN-SEPT N ?
The tax return of PHARMACIE BN-SEPT N is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE BN-SEPT N operate?
PHARMACIE BN-SEPT N operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart